

Effectiveness of Pfizer-BioNTech and Moderna Vaccines  
Among Nursing Home Residents Before and During Widespread  
SARS-CoV-2 B.1.617.2 (Delta) Variant “ National Health Security Agency  
1, 2021

Morbidity and Mortality Weekly Report  
70, 1163-1166

DOI: [10.15585/mmwr.mm7034e3](https://doi.org/10.15585/mmwr.mm7034e3)

Citation Report

#	ARTICLE	IF	CITATIONS
13	Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison â€” Texas, Julyâ€”August 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1349-1354.	9.0	50
14	Case Report of COVID-19 after Full Vaccination: Viral Loads and Anti-SARS-CoV-2 Antibodies. <i>Diagnostics</i> , 2021, 11, 1815.	1.3	8
15	Shooting at a Moving Targetâ€”Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
17	Hospitalizations Associated with COVID-19 Among Children and Adolescents â€” COVID-NET, 14 States, March 1, 2020â€”August 14, 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1255-1260.	9.0	236
19	Effectiveness of COVID-19 mRNA Vaccines Against COVID-19â€”Associated Hospitalization â€” Five Veterans Affairs Medical Centers, United States, February 1â€”August 6, 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1294-1299.	9.0	97
21	Should the world collaborate imminently to develop neglected liveâ€”attenuated vaccines for COVIDâ€”19?. <i>Journal of Medical Virology</i> , 2022, 94, 82-87.	2.5	18
22	Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions â€” United States, Marchâ€”August 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1337-1343.	9.0	358
23	Self-Testing as an Invaluable Tool in Fighting the COVID-19 Pandemic. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110477.	1.0	44
24	Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	22
26	Effectiveness of COVIDâ€”19 vaccines and their challenges (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1407.	0.8	23
33	Receptor binding domainâ€”IgG levels correlate with protection in residents facing SARSâ€”CoVâ€”2 B.1.1.7 outbreaks. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1885-1894.	2.7	13
34	Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	108
36	Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. <i>Lancet, The</i> , 2021, 398, 1407-1416.	6.3	978
39	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	13.9	675
40	Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6Months cross-sectional study. <i>Journal of Neuroimmunology</i> , 2021, 361, 577746.	1.1	63
42	Seroconversion rate after vaccination against COVID-19 in patients with cancerâ€”a systematic review. <i>Annals of Oncology</i> , 2022, 33, 158-168.	0.6	59
43	Monoclonal Antibody Use in Post-Acute and Long-Term Care: A Call to Action. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2516-2517.	1.2	0
44	The nano delivery systems and applications of mRNA. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113910.	2.6	52

#	ARTICLE	IF	CITATIONS
47	SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. <i>Science</i> , 2022, 375, 331-336.	6.0	202
48	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2043.	3.8	458
49	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	15.2	346
50	Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here. <i>BMC Public Health</i> , 2021, 21, 2084.	1.2	30
51	COVID Booster Shots: The Need of the Hour. <i>Cureus</i> , 2021, 13, e19874.	0.2	1
53	COVID-19 Incidence and hospitalization during the delta surge were inversely related to vaccination coverage among the most populous U.S. Counties. <i>Health Policy and Technology</i> , 2022, 11, 100583.	1.3	17
54	Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. <i>Journal of Infectious Diseases</i> , 2022, 225, 777-784.	1.9	21
55	Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100134.	1.5	54
56	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. <i>Cells</i> , 2021, 10, 3367.	1.8	42
58	COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly. <i>Vaccines</i> , 2021, 9, 1299.	2.1	58
59	Covid-19 Vaccine Effectiveness in New York State. <i>New England Journal of Medicine</i> , 2022, 386, 116-127.	13.9	233
60	Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
61	Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 75, e884-e887.	2.9	31
62	Epidemiology Features and Effectiveness of Vaccination and Non-Pharmaceutical Interventions of Delta and Lambda SARS-CoV-2 Variants. <i>China CDC Weekly</i> , 2021, 3, 977-982.	1.0	5
63	Coronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	22
64	mRNA-1273 and Ad26.COVS.2.S Vaccines Protect Against the B.1.621 Variant of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
66	Vaccination strategies and transmission of COVID-19: Evidence across advanced countries. <i>Journal of Health Economics</i> , 2022, 82, 102589.	1.3	23
68	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350.	13.9	501

#	ARTICLE	IF	CITATIONS
70	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
71	Evaluating immunity to SARS-CoV-2 in nursing home residents using saliva IgG. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 659-668.	1.3	7
73	Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms. <i>Journal of Disaster Research</i> , 2022, 17, 7-20.	0.4	2
74	Modeling the Impact of Vaccination Strategies for Nursing Homes in the Context of Increased Severe Acute Respiratory Syndrome Coronavirus 2 Community Transmission and Variants. <i>Clinical Infectious Diseases</i> , 2022, 75, e880-e883.	2.9	10
75	Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. <i>New England Journal of Medicine</i> , 2022, 386, 933-941.	13.9	238
77	Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1293-1305.	1.6	28
79	Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. <i>Science Immunology</i> , 2022, 7, eabn8014.	5.6	220
81	Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study. <i>International Immunopharmacology</i> , 2022, 106, 108570.	1.7	13
82	Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. <i>Emerging Microbes and Infections</i> , 2022, 11, 585-592.	3.0	50
83	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. <i>JAMA Internal Medicine</i> , 2022, 182, 197.	2.6	81
84	Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants. <i>Transfusion</i> , 2022, 62, 563-569.	0.8	7
86	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
87	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Outbreak Among Fully Vaccinated Nursing Home Residents Likely Initiated by a Fully Vaccinated Staff Member – Connecticut, July–August 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e909-e911.	2.9	6
88	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 483-495.	4.6	232
89	Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population. <i>Clinical Infectious Diseases</i> , 2022, 75, e849-e856.	2.9	23
90	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1129-1140.	1.9	65
91	Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <i>BMJ</i> , The, 2021, 375, e068848.	3.0	180
92	Bayesian Framework for Multi-Wave COVID-19 Epidemic Analysis Using Empirical Vaccination Data. <i>Mathematics</i> , 2022, 10, 21.	1.1	7

#	ARTICLE	IF	CITATIONS
93	Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study. <i>Vaccines</i> , 2021, 9, 1424.	2.1	111
94	The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis. <i>Antimicrobial Stewardship &amp; Healthcare Epidemiology</i> , 2022, 2, .	0.2	1
95	Surveillance of COVID-19 vaccine effectiveness: a real-time caseâ€“control study in southern Sweden. <i>Epidemiology and Infection</i> , 2022, 150, 1-15.	1.0	3
96	Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 557-565.	5.2	44
97	Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients. <i>Journal of Nephrology</i> , 2022, 35, 1479-1487.	0.9	18
98	Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100198.	1.5	62
99	mRNA COVIDâ€“19 vaccine effectiveness against SARSâ€“CoVâ€“2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 607-612.	1.5	7
100	Vaccine effectiveness against COVIDâ€“19 among symptomatic persons aged â‰¥12â‰“years with reported contact with COVIDâ€“19 cases, Februaryâ€“September 2021. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 673-679.	1.5	4
101	COVID-19: vaccines, efficacy and effects on variants. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 180-191.	1.2	24
102	Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis. <i>Vaccines</i> , 2022, 10, 277.	2.1	15
103	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	2.9	64
105	Trained Immunity: An Overview and the Impact on COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 837524.	2.2	35
106	Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients. <i>Journal of Nephrology</i> , 2022, 35, 769-778.	0.9	15
107	Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 566-572.	5.2	23
108	Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	20
109	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	2.9	16
110	Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac116.	0.4	15
111	The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines. <i>Health Policy and Technology</i> , 2022, 11, 100619.	1.3	7

#	ARTICLE	IF	CITATIONS
113	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.4	25
114	Covid-19 vaccines work but other factors play a relevant role: a data analysis on spread and mortality in 24 countries. Journal of Public Health Research, 2022, 11, .	0.5	0
115	COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf .	2.1	9
116	Assessment of Attitudes, Main Concerns and Sources of Knowledge Regarding COVID-19 Vaccination in Poland in the Unvaccinated Individualsâ€”A Nationwide Survey. Vaccines, 2022, 10, 381.	2.1	4
117	ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern. Antiviral Research, 2022, 199, 105271.	1.9	13
118	Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors. Clinical Infectious Diseases, 2022, 75, e564-e571.	2.9	39
119	Detection of Neutralizing Antibodies against SARS-CoV-2 Post-Vaccination in Health Care Workers of a Large Tertiary Hospital in Spain by Using a Rapid Test LFIC and sVNT-ELISA. Vaccines, 2022, 10, 510.	2.1	6
120	Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. Vaccines, 2022, 10, 469.	2.1	8
121	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Medicine, 2022, 28, 1042-1049.	15.2	61
122	Type 2 Diabetes Contributes to Altered Adaptive Immune Responses and Vascular Inflammation in Patients With SARS-CoV-2 Infection. Frontiers in Immunology, 2022, 13, 833355.	2.2	8
124	COVIDâ€”19 vaccine side effects among nursing home residents and staff. Journal of Medical Virology, 2022, 94, 3491-3493.	2.5	0
126	Longâ€”term effects of <sc>SARSâ€”CoV</sc>â€”2 vaccination in the nursing home setting. Journal of the American Geriatrics Society, 2022, 70, 1336-1341.	1.3	7
127	Inactivated vaccines prevent severe COVIDâ€”19 in patients infected with the Delta variant: A comparative study of the Delta and Alpha variants from China. Journal of Medical Virology, 2022, 94, 3613-3624.	2.5	4
128	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 â€” a review. Translational Research, 2022, 242, 1-19.	2.2	3
129	Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity. Clinical Microbiology and Infection, 2022, 28, 614.e5-614.e7.	2.8	18
130	Machine learning prediction of 3CL SARS-CoV-2 docking scores. Computational Biology and Chemistry, 2022, 98, 107656.	1.1	9
136	Covid-19â€™a karÅŸÄ± mRNA SARS-CoV2 spesifik ve ÅŸocukluk DÄŸnemi AÄŸlarÄ±. TÄŸrk DoÄŸa Ve Fen Dergisi, 2021, 10, 338-350.	0.2	0
137	Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. Vaccines, 2022, 10, 23.	2.1	37

#	ARTICLE	IF	CITATIONS
138	Increasing risk of breakthrough COVID-19 in outbreaks with high attack rates in European long-term care facilities, July to October 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	16
139	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601.		27
140	Investigation of A SARS-CoV-2 Delta (B.1.617.2) Variant Outbreak Among Residents of a Skilled Nursing Facility and Vaccine Effectiveness Analysis â€” Maricopa County, Arizona, Juneâ€“July 2021. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	1
141	SARSâ€“CoVâ€“2 Deltaâ€“variant breakthrough infections in nursing home residents at midterm after ComirnatyÂ® COVIDâ€“19 vaccination. <i>Journal of Medical Virology</i> , 2022, 94, 3776-3782.	2.5	6
142	mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. <i>Med</i> , 2022, 3, 309-324.e6.	2.2	6
143	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
144	Using high-resolution contact networks to evaluate SARS-CoV-2 transmission and control in large-scale multi-day events. <i>Nature Communications</i> , 2022, 13, 1956.	5.8	8
147	Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US. <i>JAMA Network Open</i> , 2022, 5, e228632.	2.8	7
149	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
150	The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination. <i>Vaccines</i> , 2022, 10, 696.	2.1	11
151	The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. <i>Scientific Reports</i> , 2022, 12, 7493.	1.6	8
152	Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. <i>Journal of Infectious Diseases</i> , 2022, 226, 983-994.	1.9	26
153	Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant â€” United States, February 14â€“March 27, 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 633-637.	9.0	37
154	Adults hospitalized with breakthrough COVIDâ€“19 have lower mortality than matched unvaccinated adults. <i>Journal of Internal Medicine</i> , 2022, 292, 377-384.	2.7	8
155	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. <i>Vaccines</i> , 2022, 10, 755.	2.1	13
156	Severity of Omicron SARS-CoV-2 Infection in Vaccinated and Unvaccinated Residents of Long Term Care Homes. <i>Infection Control and Hospital Epidemiology</i> , 2022, , 1-5.	1.0	0
157	SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status. <i>Nature Communications</i> , 2022, 13, 2777.	5.8	8
158	Efficacy and Safety of Sitagliptin in the Treatment of COVID-19. <i>Journal of Pharmacy Practice</i> , 2023, 36, 980-987.	0.5	4

#	ARTICLE	IF	CITATIONS
159	Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
160	Understanding "Hybrid Immunity" Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. <i>Clinical Infectious Diseases</i> , 2023, 76, e439-e449.	2.9	23
162	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
163	COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. <i>EBioMedicine</i> , 2022, 80, 104066.	2.7	30
164	Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients " implications for the omicron variant. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1417-1425.	0.3	10
165	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
166	SARS-CoV-2 pandemic in New York metropolitan area: the view from a major urgent care provider. <i>Annals of Epidemiology</i> , 2022, 74, 31-40.	0.9	6
167	Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. <i>Current Opinion in Immunology</i> , 2022, 77, 102214.	2.4	7
168	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
169	Effect of COVID-19 Vaccination Campaign in Belgian Nursing Homes on COVID-19 Cases, Hospital Admissions, and Deaths among Residents. <i>Viruses</i> , 2022, 14, 1359.	1.5	4
170	The Disparity in Hesitancy Toward COVID-19 Vaccination between Older Adults in Care Homes and Those in the Community in Taizhou, China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
171	Covid-19 and Parkinson's disease: Nursing care, vaccination and impact on advanced therapies. <i>International Review of Neurobiology</i> , 2022, , 173-196.	0.9	5
172	Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines"Effectiveness in Delta Variant Breakthrough Infections. <i>Viruses</i> , 2022, 14, 1385.	1.5	1
173	Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March"April 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S155-S158.	2.9	3
174	Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. <i>Vaccines</i> , 2022, 10, 1036.	2.1	2
175	Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
176	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. <i>Emerging Microbes and Infections</i> , 2022, 11, 1890-1899.	3.0	12
177	Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents. <i>Vaccines</i> , 2022, 10, 1098.	2.1	4



#	ARTICLE	IF	CITATIONS
178	Managing the Impact of COVID-19 in Nursing Homes and Long-Term Care Facilities: An Update. Journal of the American Medical Directors Association, 2022, 23, 1590-1602.	1.2	12
179	Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021. JAMA Network Open, 2022, 5, e2219940.	2.8	13
180	Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults. Nature Communications, 2022, 13, .	5.8	18
181	Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults. Vaccine, 2022, 40, 5050-5059.	1.7	9
182	Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. BMJ, The, 0, , e071502.	3.0	111
183	The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	4
184	Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study. The Lancet Healthy Longevity, 2022, 3, e470-e480.	2.0	22
185	Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020- November 2021. Clinical Infectious Diseases, 2022, 75, S147-S154.	2.9	4
186	Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021. JAMA Network Open, 2022, 5, e2220385.	2.8	66
187	Association of State COVID-19 Vaccine Mandates With Staff Vaccination Coverage and Staffing Shortages in US Nursing Homes. JAMA Health Forum, 2022, 3, e222363.	1.0	15
188	Site of care and factors associated with mortality in unvaccinated Australian aged care residents during COVID-19 outbreaks. Internal Medicine Journal, 2023, 53, 690-699.	0.5	1
189	Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents. Influenza and Other Respiratory Viruses, 2022, 16, 1066-1071.	1.5	7
190	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. Frontiers in Immunology, 0, 13, .	2.2	13
192	A panel regression analysis for the COVID-19 epidemic in the United States. PLoS ONE, 2022, 17, e0273344.	1.1	1
193	Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. Human Immunology, 2022, 83, 755-767.	1.2	10
194	Hesitancy about COVID-19 vaccination among pregnant women: a cross-sectional study based on the health belief model. BMC Pregnancy and Childbirth, 2022, 22, .	0.9	15
195	Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. Frontiers in Immunology, 0, 13, .	2.2	2
196	Latest in COVID-19 Vaccine 'Candidates' Race. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	0

#	ARTICLE	IF	CITATIONS
198	Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
199	Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
200	Remote infection control assessments in long-term care facilities during COVID-19 pandemic in Texas, 2020. <i>American Journal of Infection Control</i> , 2022, 50, 1110-1117.	1.1	3
201	SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain. <i>Emerging Infectious Diseases</i> , 2022, 28, 1999-2008.	2.0	12
202	Spatial Epidemiology of COVID-19 Pandemic: Disease Risk, Prognosis, and Complications. , 2022, , 241-257.		1
203	Geographic Patterns of COVID-19 Vaccination, Infection, and Mortality in the United States During YearATwo of the Pandemic and the Influence of Political Orientation. , 2022, , 341-355.		0
204	Differences in lethality and diffusion of Covid-19 in countries using different kinds of vaccines. <i>Journal of Public Health Research</i> , 2022, 11, 227990362211070.	0.5	1
205	Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. <i>Archives of Public Health</i> , 2022, 80, .	1.0	30
206	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
207	Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	5
208	Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers. <i>Biomedicines</i> , 2022, 10, 2402.	1.4	2
209	COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign. <i>Vaccine</i> , 2022, 40, 6664-6669.	1.7	5
210	Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	1
211	Broad Based Immunity?. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2022, 41, 229-230.	0.8	0
212	The Waning of BNT162b2 Vaccine Effectiveness for SARS-CoV-2 Infection Prevention over Time: A Test-Negative Study in Health Care Professionals of a Health Department from January 2021 to December 2021. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 13884.	1.2	1
213	Longitudinal serologic and viral testing postâ€“SARS-CoV-2 infection and post-receipt of mRNA COVID-19 vaccine in a nursing home cohortâ€”Georgia, October 2020â€”April 2021. <i>PLoS ONE</i> , 2022, 17, e0275718.	1.1	0
214	Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105438.	1.9	6
215	Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection. <i>MSphere</i> , 2022, 7, .	1.3	3

#	ARTICLE	IF	CITATIONS
216	Hospitalization among vaccinees for SARS-CoV-2 breakthrough infection after dose sparing strategies in Libya: A cohort study. <i>PLoS ONE</i> , 2022, 17, e0276425.	1.1	0
217	COVID-19 Trauma: The New Complex Adverse Childhood Experience. , 2022, , 177-210.		0
218	Mitigation of COVID-19 at the 2021 National Collegiate Athletic Association Men's Basketball Tournament. <i>BMC Public Health</i> , 2022, 22, .	1.2	0
219	Influencing factors of anti-SARS-CoV-2 spike IgG antibody titers in healthcare workers: A cross-section study. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	7
220	Three Outbreaks of COVID-19 in a Single Nursing Home over Two Years of the SARS-CoV-2 Pandemic. , 2023, 14, 99.		4
221	Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	2
222	Epidemiological and Genomic Analysis of a Large SARS-CoV-2 Outbreak in a Long-Term Care Facility in Catalonia, Spain. <i>MSphere</i> , 2022, 7, .	1.3	1
223	Progress Update on the Epidemiology of COVID-19 Variants and the Assessment Status of Developed Vaccines. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2022, 13, 293-299.	0.2	0
225	Black Americans Receiving the COVID-19 Vaccine and Effective Strategies to Overcome Barriers: An Integrative Literature Review. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 2577-2587.	1.8	4
226	Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16958.	1.2	1
227	Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) outbreaks in nursing homes involving residents who had completed a primary coronavirus disease 2019 (COVID-19) vaccine series—13 US jurisdictions, July–November 2021. <i>Infection Control and Hospital Epidemiology</i> , 0, , 1-5.	1.0	1
228	Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults. <i>Immunity and Ageing</i> , 2023, 20, .	1.8	10
229	Immune Response to Vaccination against COVID-19 at Different Second-Dose Intervals and Their Associations with Metabolic Parameters. <i>Vaccines</i> , 2023, 11, 149.	2.1	1
230	Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	8
231	Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation. <i>Epidemiology</i> , 2023, 34, 365-375.	1.2	7
232	Viral vaccines. , 2023, , 89-98.		0
233	Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. <i>JAMA Network Open</i> , 2023, 6, e2251974.	2.8	12
234	Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine. <i>Inflammation Research</i> , 2023, 72, 989-1000.	1.6	3

#	ARTICLE	IF	CITATIONS
235	Willingness to receive COVID-19 booster dose and its associated factors in Ghana: A cross-sectional study. <i>Health Science Reports</i> , 2023, 6, .	0.6	3
236	Deterministic and Fractional-Order Co-Infection Model of Omicron and Delta Variants of Asymptomatic SARS-CoV-2 Carriers. <i>Fractal and Fractional</i> , 2023, 7, 192.	1.6	0
237	Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2023, 71, .	1.0	4
238	Preparedness and response of assisted living facilities toward COVID-19 infection control in Houston, Texas, USA. <i>Journal of Infection Prevention</i> , 0, , 175717742311593.	0.5	0
240	Ionizable drug delivery systems for efficient and selective gene therapy. <i>Military Medical Research</i> , 2023, 10, .	1.9	2
241	Resident Factors Associated With Breakthrough SARS-CoV-2 Infections. <i>Journal of the American Medical Directors Association</i> , 2023, , .	1.2	1
242	Effectiveness of mRNA and viral vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
243	Research progress on non-protein-targeted drugs for cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	4
245	A combination of vaccination, early multiple-round overall screening, traditional Chinese medicine intervention and treatment window forward can reduce the proportion of severe and critical patients with SARS-CoV-2 B.1.617.2 (Delta) variant infection—Experience from the COVID-19 treatment center of Heilongjiang Province. <i>Journal of Translational Critical Care Medicine</i> , 2023, 5, .	0.0	0
246	Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
247	Multi-dimensional potential factors influencing COVID-19 vaccine booster acceptance and hesitancy among university academic community in Bangladesh: A cross-sectional comparative study. <i>PLoS ONE</i> , 2023, 18, e0281395.	1.1	5
248	Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models. <i>Vaccine</i> , 2023, 41, 3233-3246.	1.7	4
249	Response to the coronavirus disease 2019 pandemic of dental hygienists in South Korea—Part I: COVID-19 vaccination intentions. <i>International Journal of Dental Hygiene</i> , 2023, 21, 648-656.	0.8	0
250	Clinical Course of 53 Previously Vaccinated Patients Admitted to the National Hospital in Warsaw, Poland with COVID-19 Between November 2021 and March 2022. <i>Medical Science Monitor</i> , 0, 29, .	0.5	0
251	COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case-control study with SARS-CoV-2 genetic sequencing. <i>BMJ Open</i> , 2023, 13, e068334.	0.8	0
262	Coronavirus Vaccines. , 2023, , 248-257.e4.		0